An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Roche

Status: Completed

Conditions: Diffuse Large B-Cell Lymphoma

Study type: Observational

Funder types: Industry

Identifiers

NCT01340443

ML25435

Details and patient eligibility

About

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.

Enrollment: 314 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma
• Treatment with MabThera/Rituxan as per locally approved China package insert
• Documented patient with medical records

Exclusion criteria

• Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma

Trial design

314 participants in 1 patient group

Cohort